News

Hevolution

Find us here ...

Subscribe to our newsletter

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.

No spam - just the good stuff

More

News

Hevolution

Impetus announces $10 million for aging science research grants

Longevity investment bulletin: CohBar, Heartseed, Juvenescence and more

Hevolution Foundation announces Advancing Geroscience Efforts (HF-AGE) grant recipients

Hevolution Foundation announces $115 million Geroscience Research Opportunities Awards

Longevity investment bulletin: Longeveron, SENISCA, Form Bio and more

Hevolution and AFAR announce recipients of Aging Biology and Geroscience Awards

New Hevolution Foundation Scientific Advisory Panel set to leverage geroscience expertise

Global longevity investment hit $5.2 billion in 2022

Interviews of 2022: the longevity visionaries

Find us here ...

Subscribe to our newsletter

More